Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
KL-003 in Anemia, Sickle Cell: NCT07436767 Clinical Landscape Report 2026
16 September 2026
NCT07436767 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NM-6606 in Metabolic Dysfunction Associated Steatohepatitis: NCT07462455 Clinical Landscape Report 2026
16 September 2026
NCT07462455 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Temozolomide in Glioblastoma: NCT07457307 Clinical Landscape Report 2026
16 September 2026
NCT07457307 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Renal Cell Carcinoma: NCT07460206 Clinical Landscape Report 2026
16 September 2026
NCT07460206 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLIX1 in Glioblastoma Multiforme: NCT07464925 Clinical Landscape Report 2026
16 September 2026
NCT07464925 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EVM-18001 in Scleroderma: NCT07470151 Clinical Landscape Report 2026
16 September 2026
NCT07470151 clinical landscape for Scleroderma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BGB-58067 in Glioblastoma: NCT07485049 Clinical Landscape Report 2026
16 September 2026
NCT07485049 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HER2/ROR1 dual-target CAR-NK(Beijing Biotech/Essen BioTech) in Triple Negative Breast Cancer: NCT07486089 Clinical Landscape Report 2026
16 September 2026
NCT07486089 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab in Muscular Dystrophy, Duchenne: NCT07475754 Clinical Landscape Report 2026
16 September 2026
NCT07475754 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Retifanlimab in Glioblastoma, IDH-Wildtype: NCT07468136 Clinical Landscape Report 2026
16 September 2026
NCT07468136 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Panitumumab-IRDye800CW(Stanford University) in Pituitary Adenoma: NCT07493447 Clinical Landscape Report 2026
16 September 2026
NCT07493447 clinical landscape for Pituitary Adenoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IL13Rα2 + EGFR/EGFRvIII Dual-Target CAR-NK(Beijing Biotech) in High grade glioma: NCT07480941 Clinical Landscape Report 2026
16 September 2026
NCT07480941 clinical landscape for High grade glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.